| Autor: |
Vitta, Samhita, Kannapiran, Sushma, Shanmugam, Kirubanandan, Rao, Gagana, Balachandran, Mukeswaran, Sridhar, T. M., Ranganathan, Balu, Rajagopal, Vidhya, Ramakrishnan, Praveen |
| Předmět: |
|
| Zdroj: |
Trends in Biomaterials & Artificial Organs; 2021, Vol. 35 Issue 3, p287-295, 9p |
| Abstrakt: |
Nanoformulation of drug molecules are beneficial in terms of targeted delivery and also delivery of the drug load to the site of action. Several nanoformulation has been approved by FDA for commercial use. Cancer therapy accounts for the treatment of cancer using surgery, chemotherapy and/or radiotherapy a combination of any of these three investigations, of late targeted therapies are used for certain types of cancer, breast cancer therapy follows the same. Nanoformulations belong to the targeted delivery category. Several nanoformulation combinations with different drugs are in commercial use like PLGA, PEG-PLA and several others. This paper describes PLGA as the nanocarrier specifically for breast cancer therapy. This article describes the Synthesis of PLGA, characterization of PLGA nanoformulation using surface morphology spectroscopy analysis using Scanning Electron Microscopy (SEM), Transmission electron microscopy (TEM), and Atomic Force Microscopy (AFM). Encapsulation efficiency of the embedded drugs reported by different authors was in the range of 20 to 80% and in-vitro release kinetics in the simulated physiological solution has been detailed upon. Different breast cancer drugs used and their synergistic effect concerning the generic drug, in-vitro studies using different breast cancer cell lines and their percentage of apoptosis has been explained, in-vivo studies using different animal models and their biocompatibility and biodegradability has been described upon. Tamoxifen (Tam) embedded to PVP (polyvinyl-pyrrolidone) and PLGA reported showing increased tumor necrosis. Parenteral administration of doxorubicin (DOX)- loaded PEG-b- PLGA nanoformulation at 5 mg/kg of DOX very effectively inhibited tumor growth in comparison with free generic DOX at the same dosage. Finally about the FDA approved available in the commercial market has been elaborated. The prospect of undergoing clinical trials of the nanoformulations will be worked upon. In the due course of time, more FDA approvals are in the pipeline for PLGA based nanoformulations to be translated into nanomedicine for precise personalized medicine for breast cancer therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
